+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Promising Outlook - US Cancer Vaccine Market

  • ID: 4495589
  • Report
  • August 2018
  • Region: United States
  • 135 Pages
  • RNCOS E-Services Private Limited
Cancer Vaccines have Always been Considered as High Potential Method for Preventing and Treating Cancer even Though they have not been Able to Achieve Their Expected Sales


  • Amgen Inc.
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
Cancer involves abnormal and uncontrolled cell growth which may spread to other parts of the body as well. According to GLOBOCAN, in 2015, approximately 15.2 Million incidences of cancer were registered all across the globe. Out of total, US accounted for approximately 1.7 Million incidences of this deadly disease. Cancer is also one of the leading causes of mortality. Traditional treatment options, such as surgery, chemotherapy and radiotherapy, have several drawbacks such as hair loss, abnormal blood cell count and nausea. One of the major drawbacks of traditional cancer treatment therapies is the risk of remission in patient.

Owing to all these shortcomings, researchers are developing novel treatment options, such as cancer vaccines, for this disease. Cancer vaccines have always been considered as high potential method for preventing and treating cancer even though they have not been able to achieve their expected sales. However, the market for these vaccines is expected to witness decent growth in the coming years due to the launch of new cancer vaccines and increasing awareness among people about this treatment option.

According to this report entitled “Promising Outlook - US Cancer Vaccine Market”, the US is largest market for cancer vaccines amongst all the geographic regions worldwide. The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing cancer incidences in the country, rising awareness, and strong pipeline, for the US Cancer Vaccines Market. Furthermore, the report also gives information related to the commercially available cancer vaccines. It also covers the restraints hampering the growth of the market, and future opportunities.

On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounted for the largest share in 2017. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline.

Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.

The prominent players in US Cancer Vaccines Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the US Cancer Vaccines Market.
Note: Product cover images may vary from those shown


  • Amgen Inc.
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.

1. Analyst View2. Research Methodology
3. Cancer Statistics by Demographics
3.1 Prevalence, Incidences and Mortality
3.2 Leading States by Incidences
3.3 Leading Cancers by Incidences
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Children Cancer Incidences
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Cancer Incidences
4.1.2 Ability to Reduce Healthcare Expenditure
4.1.3 Rising Awareness
4.1.4 Patient Assistance Programs
4.1.5 Government Initiatives
4.1.6 Strong Pipeline
4.1.7 Technological Advancements
4.2 Restraints
4.2.1 High Cost of Cancer Vaccines
4.2.2 Side-Effects of Cancer Vaccines
4.2.3 Vaccine Supply Shortages
4.2.4 Insurance Issues Related to Cancer Vaccination
4.3 Opportunities
4.3.1 Therapeutic Cancer Vaccines
4.3.2 Adjuvant Cancer Vaccines
5. Cancer Vaccines Market Outlook
5.1 Key Product Analysis
5.1.1 Provenge Market Analysis
5.1.2 T-Vec/Imlygic Market Analysis
5.1.3 HPV Vaccine Gardasil Market Analysis Cervarix Market Analysis
5.1.4 HBV Vaccines Engerix-B & Twinrix Market Analysis Recombivax HB Market Analysis Pediarix/ Infanrix Market Analysis
6. Cancer Vaccines Market by Cancer Type7. Cancer Vaccine Market by Application
8. Potential Cancer Vaccine Candidates: An Opportunity Assessment
8.1 Prophylactic Vaccine
8.2 Therapeutic Vaccine
8.2.1 Prostate Cancer
8.2.2 Breast Cancer
8.2.3 Lung Cancer
8.2.4 Colorectal Cancer
9. US Patent Analysis
9.1 Patents by Year
9.2 Patents by Category
9.2.1 Utility Patents
9.2.2 Design Patents
9.2.3 Plant Patents
9.3 Patents by Company
9.4 Patents by Assignee Type
9.4.1 By Assignee Name
9.4.2 By Assignee State
10. Regulatory Environment
10.1 Vaccine Approval Process
10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
10.2.1 Considerations for both Early and Late Phase Clinical Trials Patient Population Monitoring the Immune Response Biomarkers as Evidence of Efficacy Adjuvants Used to Stimulate Immune Response Multi-antigen Vaccines Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines Concomitant and Subsequent Therapies
10.2.2 Considerations for Early Phase Clinical Trials Starting Dose and Dosing Schedule Booster and Maintenance Therapy Dose Escalation Single-arm versus Randomized Phase-2 Trials in Early Development
10.2.3 Considerations for Late Phase Clinical Trials Safety Profile from Early Phase Clinical Trials Endpoints Statistical Issues Control Issues Delayed Vaccine Effect Autologous Vaccine Trials Accelerated Approval Regulations
11. Competitive Landscape
12. Company Profiles
12.1 Merck & Co., Inc.
12.2 GlaxoSmithKline plc.
12.3 Dendreon Pharmaceuticals LLC
12.4 Amgen Inc.
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • Dendreon Pharmaceuticals LLC
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
Note: Product cover images may vary from those shown